ArticleAsian Pacific journal of cancer prevention : APJCP2025
Thiosemicarbazone Complexes and 6-MP Suppress Acute Lymphoblastic Leukemia via the NOTCH Signaling Pathway and Regulation of LUNAR1 and NALT1 lncRNA.
Article in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- From epigenetics to metastasis: Multifaceted roles of lncRNAs in gastric cancer.Biochemistry and biophysics reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute Lymphoblastic Leukemia (ALL) is the most common type of leukemia among children. There are several types of drugs that are common in treating and controlling leukemia, including 6-M. Moreover, the anti-cancer effects of the Thiosemicarbazone-Ni complex were surveyed as well as 6-MP. The current study aimed to evaluate the effect of the Thiosemicarbazone-Ni complex in comparison with 6-MP on the expression of NALT1 and LUNAR1 LncRNAs and their target gene, NOTCH1, in the Jurkat E6.1 cell line. MATERIALS AND
methodsJurkat E6.1 cell was treated with 6-MP with the concentrations of 1, 5, 10, and 25μM and 0.5, 1, 2, and 5μM of Ni-nanoparticles, loaded with Thiosemicarbazone complexes for 24, 48, and 72 h. Subsequently, the RNA extraction and cDNA synthesis were performed and the expression of NALT1, LUNAR1, NOTCH1, and GAPDH genes was surveyed by Real-time PCR. Finally, the results were analyzed by statistical analysis.
resultsThe highest significant reduction in the expression of LUNAR1 was observed at 6-MP at 10μM for the first 72 h and the Thiosemicarbazone-Ni complex showed its effective dose at 5μM for 48 h. The highest decrease in NOTCH1 expression was observed in 6-MP treatment at 10μM concentration for 24h and Ni-Thiosemicarbazone treatment, the significant decrease was at 0.5μM for 72h. The most significant reduction in NALT1 expression was observed in treatment with Ni-Thiosemicarbazone complex and 6-MP at the concentrations of 2 and 10μM respectively for 24h.
conclusionGiven the association between the aforementioned genes and the positive effects of the drugs at achieved concentrations and times, it can be concluded that Thiosemicarbazone-Ni complex and 6-MP can show putative roles in regulating the expression of studied genes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.